Is Renalytix Stock a Good Investment?
Renalytix Investment Advice | RNLX |
- Examine Renalytix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Renalytix's leadership team and their track record. Good management can help Renalytix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Technology space and any emerging trends that could impact Renalytix's business and its evolving consumer preferences.
- Compare Renalytix's performance and market position to its competitors. Analyze how Renalytix is positioned in terms of product offerings, innovation, and market share.
- Check if Renalytix pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Renalytix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Renalytix AI stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Renalytix AI is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Renalytix Stock
Researching Renalytix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.62. Renalytix AI had not issued any dividends in recent years.
To determine if Renalytix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Renalytix's research are outlined below:
| Renalytix AI generated a negative expected return over the last 90 days | |
| Renalytix AI has high historical volatility and very poor performance | |
| Renalytix AI has some characteristics of a very speculative penny stock | |
| Renalytix AI has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.29 M. Net Loss for the year was (33.46 M) with profit before overhead, payroll, taxes, and interest of 720 K. | |
| Renalytix AI currently holds about 32.36 M in cash with (30.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Renalytix AI has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Renalytix plc Reports Financial Results for First Quarter of Fis - GuruFocus.com |
Renalytix Quarterly Accounts Payable |
|
Renalytix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Renalytix AI. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Renalytix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 14th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Renalytix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Renalytix's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-15 | 2024-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-12-07 | 2021-09-30 | -0.12 | -0.14 | -0.02 | 16 | ||
2024-02-15 | 2023-12-31 | -0.09 | -0.18 | -0.09 | 100 | ||
2021-06-15 | 2021-03-31 | -0.145 | -0.24 | -0.095 | 65 | ||
2023-09-28 | 2023-06-30 | -0.13 | -0.24 | -0.11 | 84 | ||
2023-11-15 | 2023-09-30 | -0.1 | -0.22 | -0.12 | 120 | ||
2020-11-25 | 2020-09-30 | -0.07 | -0.2 | -0.13 | 185 | ||
2023-03-30 | 2022-12-31 | -0.14 | -0.28 | -0.14 | 100 |
Know Renalytix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Renalytix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Renalytix AI backward and forwards among themselves. Renalytix's institutional investor refers to the entity that pools money to purchase Renalytix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 24.7 K | Xtx Topco Ltd | 2024-09-30 | 20.2 K | Lpl Financial Corp | 2024-09-30 | 18.4 K | Ewa, Llc | 2024-06-30 | 16.5 K | Jpmorgan Chase & Co | 2024-06-30 | 16.2 K | Baader Bank Inc | 2024-09-30 | 15 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 14.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 12.9 K | Virtu Financial Llc | 2024-06-30 | 12.5 K | Pinnacle Associates Inc | 2024-09-30 | 846.5 K | Stifel Financial Corp | 2024-06-30 | 561 K |
Renalytix's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.55 M.Market Cap |
|
Renalytix's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.20) | (4.41) | |
| Return On Capital Employed | 8.40 | 7.74 | |
| Return On Assets | (4.20) | (4.41) | |
| Return On Equity | 4.26 | 4.05 |
Determining Renalytix's profitability involves analyzing its financial statements and using various financial metrics to determine if Renalytix is a good buy. For example, gross profit margin measures Renalytix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Renalytix's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Renalytix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Renalytix AI. Check Renalytix's Beneish M Score to see the likelihood of Renalytix's management manipulating its earnings.
Evaluate Renalytix's management efficiency
Renalytix AI has return on total asset (ROA) of (0.9354) % which means that it has lost $0.9354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.7318) %, meaning that it created substantial loss on money invested by shareholders. Renalytix's management efficiency ratios could be used to measure how well Renalytix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -4.41 in 2024. Return On Capital Employed is likely to drop to 7.74 in 2024. At this time, Renalytix's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 7.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.07) | (0.07) | |
| Tangible Book Value Per Share | (0.07) | (0.07) | |
| Enterprise Value Over EBITDA | (1.09) | (1.14) | |
| Price Book Value Ratio | (3.46) | (3.63) | |
| Enterprise Value Multiple | (1.09) | (1.14) | |
| Price Fair Value | (3.46) | (3.63) | |
| Enterprise Value | 31 M | 29.4 M |
The decision-making processes within Renalytix are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 2.103 |
Basic technical analysis of Renalytix Stock
As of the 25th of November, Renalytix holds the Variance of 42.14, risk adjusted performance of (0.1), and Coefficient Of Variation of (707.77). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Renalytix, as well as the relationship between them.Renalytix's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Renalytix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Renalytix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Renalytix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Icahn School Of Medicine At Mount Sinai over three weeks ago Acquisition by Icahn School Of Medicine At Mount Sinai of 13366750 shares of Renalytix at 0.116 subject to Rule 16b-3 | ||
Jung Joel R over three months ago Acquisition by Jung Joel R of 60000 shares of Renalytix at 0.2067 subject to Rule 16b-3 | ||
Jung Joel R over six months ago Insider Trading | ||
Icahn School Of Medicine At Mount Sinai over six months ago Acquisition by Icahn School Of Medicine At Mount Sinai of 9360374 shares of Renalytix at 0.25 subject to Rule 16b-3 | ||
Coste Catherine over a year ago Acquisition by Coste Catherine of 95000 shares of Renalytix subject to Rule 16b-3 | ||
Mclain Thomas H over a year ago Acquisition by Mclain Thomas H of 200000 shares of Renalytix subject to Rule 16b-3 |
Renalytix's Outstanding Corporate Bonds
Renalytix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Renalytix AI uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Renalytix bonds can be classified according to their maturity, which is the date when Renalytix AI has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NECELE 217 25 NOV 26 Corp BondUS75972BAB71 | View | |
| RENAISSANCERE FIN INC Corp BondUS75973QAA58 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| RENIASSANCERE FIN INC Corp BondUS75972YAA91 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Renalytix's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Renalytix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 2.71 | |||
| Mean Deviation | 5.07 | |||
| Coefficient Of Variation | (707.77) | |||
| Standard Deviation | 6.49 | |||
| Variance | 42.14 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.95) | |||
| Treynor Ratio | 2.7 | |||
| Maximum Drawdown | 34.92 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 7.14 | |||
| Skewness | (0.79) | |||
| Kurtosis | 1.55 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 2.71 | |||
| Mean Deviation | 5.07 | |||
| Coefficient Of Variation | (707.77) | |||
| Standard Deviation | 6.49 | |||
| Variance | 42.14 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.95) | |||
| Treynor Ratio | 2.7 | |||
| Maximum Drawdown | 34.92 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 7.14 | |||
| Skewness | (0.79) | |||
| Kurtosis | 1.55 |
Consider Renalytix's intraday indicators
Renalytix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Renalytix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Renalytix time-series forecasting models is one of many Renalytix's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Renalytix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Renalytix Stock media impact
Far too much social signal, news, headlines, and media speculation about Renalytix that are available to investors today. That information is available publicly through Renalytix media outlets and privately through word of mouth or via Renalytix internal channels. However, regardless of the origin, that massive amount of Renalytix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Renalytix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Renalytix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Renalytix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Renalytix alpha.
Renalytix Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Renalytix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Renalytix Corporate Management
| Oliver III | Chief Officer | Profile | |
| Jean Casner | VP Officer | Profile | |
| Baljit Singh | Head Operations | Profile | |
| Howard Doran | Chief Officer | Profile | |
| Salim FCA | Company Secretary | Profile | |
| Fergus Fleming | Chief Officer | Profile | |
| Andria ParksHerrera | VP Marketing | Profile |
Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.